# Medication Discovery Using Rat Models of Relapse. Period of Performance: 7/10/2019-7/9/2021. N01DA-19-8949

> **NIH NIH N01** · VIRGINIA COMMONWEALTH UNIVERSITY · 2020 · $1,156,293

## Abstract

The objective of this contract is to determine the in vivo efficacy of novel compounds in animal models of relapse using cocaine, nicotine, methamphetamine, or opioids. This includes the following tests in animals trained to self- administer cocaine (for example): (1) the ability of a test compound to block footshock or other stressor-induced reinstatement of responding after a period of experimental extinction; (2) the ability of a test compound to block or reduce priming-induced reinstatement of responding after a period of extinction; and (3) the ability of a test compound to block the effects of a conditioned cue (previously paired with the training drug) to reinstate responding for the training drug after a period of extinction.

## Key facts

- **NIH application ID:** 10285339
- **Project number:** 75N95019C00029-P00001-9999-2
- **Recipient organization:** VIRGINIA COMMONWEALTH UNIVERSITY
- **Principal Investigator:** —
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,156,293
- **Award type:** —
- **Project period:** 2019-07-10 → 2021-07-09

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10285339

## Citation

> US National Institutes of Health, RePORTER application 10285339, Medication Discovery Using Rat Models of Relapse. Period of Performance: 7/10/2019-7/9/2021. N01DA-19-8949 (75N95019C00029-P00001-9999-2). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10285339. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*